Observational studyThe Journal of international medical research2026
Kidney cancer burden in China from 1990 to 2023: A retrospective population-based observational study.
Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo assess long-term trends in kidney cancer burden in China from 1990 to 2023 and estimate the proportion of this burden attributable to major modifiable risk factors.MethodsThis retrospective, population-based observational study used China-specific estimates from the Global Burden of Disease Study (2023). All-age numbers and age-standardized rates for incidence, mortality, prevalence, and disability-adjusted life years, along with 95% uncertainty intervals, were obtained. Joinpoint regression was used to calculate the average annual percentage change by sex and age group.ResultsIn 2023, there were 61,323 new kidney cancer cases and 21,784 kidney cancer-related deaths in China. Compared with 1990, the incident and prevalent cases increased by 214.48% and 251.46%, respectively. The age-standardized incidence rate, age-standardized mortality rate, and age-standardized prevalence rate increased, whereas the age-standardized disability-adjusted life year rate declined. The kidney cancer burden was higher in men than in women. The prevalence was highest in the 50-74 years age group, whereas the ≥75 years age group demonstrated the greatest relative increase. Smoking, high body mass index, and trichloroethylene exposure accounted for substantial estimated attributable kidney cancer deaths and disability-adjusted life years.ConclusionsThe absolute burden of kidney cancer in China increased substantially from 1990 to 2023, particularly among men and older adults. These findings may support age- and sex-informed prevention strategies, tobacco control, weight management, occupational exposure reduction, and improved monitoring of high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.